MARKET

ONCT

ONCT

Oncternal Therapeutics Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.940
+0.139
+4.94%
Closed 16:00 04/08 EDT
OPEN
2.761
PREV CLOSE
2.802
HIGH
2.980
LOW
2.760
VOLUME
2.70K
TURNOVER
--
52 WEEK HIGH
9.80
52 WEEK LOW
2.240
MARKET CAP
45.24M
P/E (TTM)
-0.6761
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 1 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average ONCT stock price target is 1.500 with a high estimate of 1.500 and a low estimate of 1.500.

EPS

ONCT News

More
  • Is Oncternal Therapeutics (NASDAQ:ONCT) In A Good Position To Invest In Growth?
  • Simply Wall St. · 03/18 13:36
  • Oncternal Therapeutics reports Q4 results
  • seekingalpha · 03/17 01:07
  • Oncternal Therapeutics, Inc. (ONCT) CEO Dr. Jim Breitmeyer on Q4 2019 Results - Earnings Call Transcript
  • Seeking Alpha - Transcript · 03/17 00:06
  • Oncternal Provides Business Update and Announces Fourth Quarter and Full Year 2019 Financial Results
  • Business Wire · 03/16 21:05

Industry

Biotechnology & Medical Research
+3.06%
Pharmaceuticals & Medical Research
+2.82%

Hot Stocks

Symbol
Price
%Change

About ONCT

Oncternal Therapeutics, Inc., formerly GTX, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of product candidates for the treatment of cancers. Its pipeline includes cirmtuzumab, TK-216 and chimeric antigen receptor T-cell (CAR-T). Its cirmtuzumab product candidate is an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) monoclonal antibody. Cirmtuzumab is in a Phase-I/II clinical trial in combination with ibrutinib for the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). TK216 is a small-molecule compound designed to inhibit the biological activity of E26 transformation-specific (ETS) oncoproteins. TK216 is being evaluated in combination with vincristine in a Phase-I clinical trial in patients with relapsed or refractory Ewing sarcoma. Its CAR-T product candidate targets ROR-1 and is in preclinical development as a treatment for hematologic cancers and solid tumors.
More

Webull offers kinds of Oncternal Therapeutics Inc stock information, including NASDAQ:ONCT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ONCT stock news, and many more online research tools to help you make informed decisions.